Grow Therapy

Grow Therapy Competitive Intelligence & Landscape

growtherapy.com ·

Overview

Grow Therapy Overview

Grow Therapy is a private, rapidly growing online mental health platform founded in 2020 and headquartered in New York City. It specializes in connecting individuals with licensed therapists through a digital platform that offers both virtual and in-person therapy sessions (Exa, PitchBook). The company's core services include matching clients with therapists based on their preferences, insurance coverage, and specific mental health needs, with a focus on making therapy accessible, affordable, and flexible (Grow Therapy).

Grow Therapy's target market encompasses individuals seeking mental health support, including those with insurance plans, and mental health providers looking to expand their practices. The platform supports over 1,977 employees and has raised substantial funding, including a Series D round of $150 million, reflecting its significant market presence and growth trajectory (Bitscale, PitchBook). Its mission is to make mental health care more accessible and effective by simplifying the process of finding and providing therapy, emphasizing personalized, stigma-free care that fits into real life.

Grow Therapy

Grow Therapy Weekly Intel Updates

Receive weekly intel updates about Grow Therapy straight to your inbox.

Competitors

Grow Therapy Competitors

Rula stands out as a key competitor to Grow Therapy due to its broader range of specialties, including child and teen counseling, and its focus on virtual care, although it offers limited tools for ongoing support compared to Grow Therapy (growtherapy.com).

Alma is another significant competitor, known for its affordability, extensive insurance coverage, and flexibility, making it a popular choice for those seeking both virtual and in-person therapy options (growtherapy.com).

Headway and Tava are also notable, with Headway providing a large network of providers and Tava emphasizing its integrated care approach, although specific feature comparisons are less detailed in the current sources (dreavita.com). Additionally, GlobalMed and Wellth offer alternative mental health solutions, but they focus more on medication adherence and broader health management rather than direct therapy services (aviahealth.com). Overall, Grow Therapy’s competitive edge lies in its insurance acceptance, practice growth tools, and hybrid service model, positioning it strongly in the rapidly expanding online therapy market (cbinsights.com).

Product & Pricing

Grow Therapy Product and Pricing Intelligence

Grow Therapy offers a flexible, subscription-free mental health care model, where clients pay per session rather than through a fixed subscription plan. As of late 2025, the typical cost per session ranges from $0 to $50 when using insurance, with out-of-pocket rates varying from $75 to $200 depending on the provider and location (Grow Therapy, Grow Therapy). The platform accepts most major insurances, which significantly reduces the cost for clients, with an average session cost with insurance around $21 (Grow Therapy, Grow Therapy). Recent updates indicate that clients can verify their insurance coverage directly through Grow Therapy’s tools to see personalized cost estimates, and the company emphasizes the importance of understanding individual insurance benefits for mental health services (Grow Therapy, Grow Therapy). Grow Therapy’s pricing structure is designed to be transparent, with clients able to find providers that accept their insurance and pay as little as $21 per session on average with insurance, making mental health care more accessible and affordable (Grow Therapy, Grow Therapy). Overall, Grow Therapy’s product and pricing model focus on affordability, flexibility, and insurance integration, with recent pricing updates emphasizing the platform’s commitment to reducing barriers to mental health care.

Ad Campaigns

Grow Therapy Ad Campaigns

Grow Therapy is currently running 4,745 ads across Google, Meta (Facebook & Instagram), LinkedIn — 492 on Meta, 4,000 on Google and 253 on LinkedIn. Explore Grow Therapy's live ad creative, messaging, and the platforms they advertise on in the ad library — updated automatically by ForesightIQ.

See of Grow Therapy's ads

View ads

Hiring & Layoffs

Grow Therapy Hiring and Layoffs

Recent developments at Grow Therapy indicate a strong growth trajectory and strategic expansion in the mental health sector. As of March 2026, the company raised $150 million in Series D funding, led by TCV and Goldman Sachs Alternatives, to expand its partnerships with employers and health systems, signaling a focus on scaling its support network and improving access to mental health services (MedCity News). This substantial investment underscores Grow Therapy's commitment to broadening its reach and solidifying its position as a key player in mental health care delivery.

In terms of hiring, Grow Therapy continues to build its team, emphasizing a culture of innovation, well-being, and remote work flexibility. The company has posted numerous job openings across various roles, including healthcare providers, administrative, and technical positions, reflecting its rapid growth and ongoing efforts to enhance its platform and services (Grow Therapy Careers, Remotive). Although specific recent layoffs are not reported, the company's aggressive expansion and funding activities suggest a strategic focus on scaling operations and strengthening its infrastructure.

Overall, Grow Therapy's hiring patterns and recent funding round signal a strategic focus on growth, technological enhancement, and market expansion. Their emphasis on building a large, integrated network of providers and partnerships aligns with their mission to make mental health care more accessible and affordable, positioning them as a rapidly evolving leader in the digital mental health landscape.

Leadership

Grow Therapy Management and Leadership Team

The leadership and management team of Grow Therapy is led by CEO and Co-Founder Jake Cooper, who has a background with Blackstone and Apollo Global Management (The Org). The company has experienced recent leadership developments, including the appointment of new leaders in marketing, data, and design as of October 2025, to support its growth and expansion efforts (Grow Therapy Blog).

The executive team comprises around six key members, with Jake Cooper serving as the current CEO and founder, and other leaders contributing to operations, technology, and clinical services (CB Insights). Additionally, Grow Therapy has made strategic hires at the C-suite level, including roles focused on marketing, data, and design, to enhance its platform and clinical offerings (Grow Therapy Blog).

Recent updates also highlight the company's rapid growth, with Series D funding of $150 million led by TCV and Goldman Sachs, aiming to expand mental health access across the US (Grow Therapy Blog). The company’s leadership continues to evolve with a focus on innovation, accessibility, and scaling its mental health services, supported by a team of over 460 employees, including 125 in product and tech roles (LeadIQ).

Financials

Grow Therapy Financial Performance, Fundraising, M&A

Grow Therapy has demonstrated significant financial growth and active fundraising efforts since its founding in 2020. The company has raised a total of $178 million across seven funding rounds, with the latest Series C round raising $88 million in April 2024, led by Sequoia Capital and other prominent investors (CB Insights). The company's valuation has been estimated based on its funding rounds and market activity, although specific valuation figures are not publicly disclosed.

Financial health indicators suggest that Grow Therapy is expanding rapidly, with a reported 2022 revenue of $50 million. Its recent Series D funding round in March 2026, which raised $150 million led by TCV and Goldman Sachs, underscores strong investor confidence and growth potential (PitchBook, Grow Therapy Blog). The company’s focus on scaling its mental health platform and increasing access to therapy services has contributed to its valuation and market presence.

In terms of mergers and acquisitions, there are no publicly available reports of recent acquisitions involving Grow Therapy. However, its active fundraising and strategic partnerships with major investors like Sequoia, TCV, and Goldman Sachs indicate a focus on growth and market expansion within the mental health technology sector. Overall, Grow Therapy appears to be financially healthy and poised for continued growth, driven by robust funding, increasing revenue, and a growing user base (CB Insights).

Partnerships

Grow Therapy Partnerships, Clients and Vendors

Grow Therapy has established a robust network of partnerships, clients, and vendors to enhance mental health care delivery. Notably, the company has formed partnerships with over 125 payers, including major health systems like Kaiser Permanente and provider groups such as Circle Medical, facilitating broad access to insurance-covered mental health services (fiercehealthcare). The company’s collaborations extend to health plans like Blue Cross Blue Shield and Anthem, enabling in-network therapy options across various states (growtherapy.com). Additionally, Grow Therapy has partnered with primary care providers to integrate mental health services into primary care settings, addressing the significant role of primary care physicians in delivering mental health care, which accounts for 60% of mental health services in the U.S. (wolterskluwer).

In terms of enterprise clients, Grow Therapy serves large health systems, employers, and Medicaid plans, notably through its recent $150 million Series D funding round led by TCV and Goldman Sachs Alternatives. This capital infusion aims to expand physician and employer relationships, further integrating Grow’s platform into the healthcare ecosystem and improving access to mental health care (fiercehealthcare). The company also focuses on empowering independent therapists by providing credentialing, referral networks, administrative support, and technology tools such as EHR, secure messaging, and e-prescribing, which are integrated into its ecosystem (growtherapy.com).

Grow Therapy’s technology integrations include advanced telehealth tools, measurement-informed care, and AI-powered summarization to improve clinical practice and patient outcomes. Its ecosystem relationships extend to collaborations with health insurers, provider groups, and employer-sponsored health plans, making it a key player in the digital mental health landscape (growtherapy.com, transformcap.com). Overall, Grow Therapy’s strategic partnerships, enterprise client base, and technology integrations position it as a leading innovator in accessible mental health care.

Events

Grow Therapy Event Participations

Grow Therapy actively participates in various industry events and community engagement activities to support and connect with mental health professionals. Notably, they were featured at the Behavioral Health Tech Conference (BHT2023) held in Phoenix, Arizona, from November 14-17, 2023, where they showcased their innovative telehealth tools and discussed advancements in mental health care technology (Grow Therapy). Additionally, Grow Therapy has launched and promoted a Provider Spotlight Program, which offers exclusive opportunities for providers to collaborate with their marketing team, writers, and journalists, fostering professional growth and visibility (Grow Therapy Blog). They also sponsor and host community events, including peer-to-peer support sessions, clinical resource sharing, and networking opportunities through their Grow Community, which boasts over 19,000 members (Grow Therapy Community). These initiatives demonstrate Grow Therapy’s commitment to industry engagement, professional development, and community support within the mental health field.

Frequently Asked Questions

What does Grow Therapy's $150M Series D in March 2026, led by TCV and Goldman Sachs, signal about where the company is placing its next strategic bets?

The Series D signals a deliberate pivot toward enterprise and institutional channels rather than purely consumer-direct growth. The stated use of proceeds is expanding partnerships with employers and health systems, and the choice of TCV and Goldman Sachs Alternatives as lead investors — rather than purely health-focused VCs — suggests Grow Therapy is positioning for large-scale B2B distribution and potentially a future liquidity event. This follows the April 2024 Series C of $88 million led by Sequoia, indicating a rapid acceleration in capital deployment over roughly two years.

Grow Therapy's hiring in October 2025 focused on new leadership in marketing, data, and design. What does that cluster of hires reveal about internal gaps or strategic priorities?

Hiring simultaneously into marketing, data, and design at the leadership level suggests Grow Therapy recognized it was under-built in brand differentiation, analytics infrastructure, and product experience relative to its growth stage. These are functions that typically lag behind a company's first scaling phase and become critical as it moves upmarket toward employer and health system buyers who require more sophisticated reporting, positioning, and polished product surfaces. The timing — ahead of the Series D close — also points to preparation for an enterprise go-to-market push.

Grow Therapy reported $50M in revenue in 2022 and has since raised over $300M in cumulative funding. Is this financial trajectory a sign of healthy scaling or a cash-burn concern?

The trajectory is ambiguous without more recent revenue figures. The $50M 2022 revenue figure against total disclosed funding of roughly $328M (including the Series D) implies heavy capital intensity, which is common in provider-network businesses where credentialing, payer contracting, and provider support are costly. Investor confidence from Sequoia, TCV, and Goldman Sachs lends credibility to the model, but the absence of disclosed profitability metrics or updated revenue figures means analysts should treat burn rate as an open question. ForesightIQ continues to track updated financial signals as they emerge.

What does Grow Therapy's network of 125+ payer partnerships — including Kaiser Permanente, Blue Cross Blue Shield, and Anthem — tell us about its defensibility versus competitors like Headway and Alma?

A payer network of this scale creates a meaningful structural moat: in-network status directly drives client acquisition because patients follow their insurance coverage. Competitors like Headway and Alma also compete on insurance acceptance, but Grow Therapy's explicit partnerships with large integrated systems like Kaiser Permanente suggest it is winning at the health-system level, not just individual payer contracts. This is harder to replicate quickly and positions Grow Therapy well for the employer and Medicaid expansion targeted by the Series D.

Grow Therapy is now explicitly targeting employer and health system partnerships with its latest funding round. How does this change the competitive dynamics with Rula, Alma, and Headway?

Moving upmarket into enterprise employer and health system channels shifts Grow Therapy's primary competition from consumer-facing platforms like Rula and Alma toward players with established B2B sales infrastructure, such as Headway and potentially Lyra Health or Spring Health (not in the disclosed material but relevant context). Rula and Alma compete more heavily on therapist-facing tools and consumer UX, while Grow Therapy appears to be differentiating on payer depth and enterprise integration. The risk is execution complexity: employer and health system sales cycles are long and require compliance, reporting, and outcomes infrastructure that consumer-first companies often underestimate.

CEO Jake Cooper came from Blackstone and Apollo Global Management before founding Grow Therapy. How does that background shape the company's strategic and financial posture?

A background in private equity at Blackstone and Apollo typically produces founders who are acutely focused on unit economics, capital structure, and exit optionality — not just top-line growth. This likely explains the disciplined progression through funding rounds (seed through Series D with named institutional leads) and the B2B pivot toward employers and health systems, which tend to generate more predictable, contractual revenue streams. It also means Cooper is likely building toward a defined liquidity outcome, whether IPO or strategic acquisition, rather than an indefinite growth-stage company.

Grow Therapy's provider community has over 19,000 members. What does that figure signal about its strategy for provider acquisition and retention relative to competitors?

A 19,000-member provider community is a significant supply-side asset that goes beyond the platform's licensed therapist network — it functions as a retention and referral mechanism. By embedding providers in a peer community with clinical resources, peer support, and marketing opportunities like the Provider Spotlight Program, Grow Therapy reduces churn among its therapist supply, which is a known vulnerability for marketplace-model mental health platforms. Competitors like Alma also invest heavily in provider community, so the differentiator lies in the scale and engagement quality of Grow Therapy's community, which ForesightIQ tracks through provider sentiment signals.

What does Grow Therapy's pricing model — averaging $21 per session with insurance — mean for its competitive positioning against subscription-based alternatives like BetterHelp and Talkspace?

The $21 average with insurance is a structurally lower price point than subscription platforms like BetterHelp (~$65/week) and Talkspace (~$69/week), but it requires insurance coverage to achieve, meaning the value proposition is conditional on Grow Therapy's payer network depth. For insured consumers, this is a decisive advantage and a key acquisition lever. The risk is that uninsured or underinsured populations remain underserved, and out-of-pocket rates of $75–$200 per session on Grow Therapy's platform are not materially different from competitors in that segment.

Grow Therapy is integrating AI-powered summarization and measurement-informed care tools into its platform. What does this product direction signal about where it is trying to differentiate with health system buyers?

Health systems and employers evaluating mental health platforms increasingly require outcomes data and clinical documentation efficiency to justify network inclusion and value-based contracts. AI summarization directly addresses therapist administrative burden, which is a top attrition driver, while measurement-informed care generates the outcomes data that enterprise buyers demand. This product direction signals Grow Therapy is building toward clinical outcomes accountability — a higher bar than consumer convenience — which is the right posture for health system partnerships but requires credible evidence generation to win and retain those contracts.

Grow Therapy is partnering with primary care providers to integrate mental health services, citing that PCPs deliver 60% of mental health care in the U.S. How material is this channel, and what does it signal strategically?

The PCP integration channel is potentially one of the highest-value distribution moves in the company's portfolio because it intercepts mental health need at the point of first clinical contact, dramatically reducing the consumer acquisition friction that plagues direct-to-consumer telehealth. If Grow Therapy can embed referral workflows into primary care settings — particularly through its Circle Medical partnership — it creates a referral flywheel that competitors without health system relationships cannot easily replicate. This channel also aligns with Medicaid and employer health plan requirements for coordinated care, reinforcing the enterprise strategy funded by the Series D.

Grow Therapy has raised funding across seven rounds totaling roughly $328M with no disclosed acquisitions. Does the absence of M&A activity represent strategic discipline or a missed opportunity?

The absence of acquisitions through a period of aggressive funding rounds suggests either disciplined focus on organic platform scaling or a deliberate decision to avoid integration risk while the core business is still maturing. Given that the mental health tech market has seen distressed assets — companies like Cerebral and others facing regulatory and operational challenges — Grow Therapy may have had acquisition opportunities. The most likely explanation is that management, given Cooper's PE background, is preserving capital efficiency and balance sheet optionality ahead of a potential liquidity event rather than complicating the story with integration risk.

Grow Therapy appeared at BHT2023 in November 2023 and runs a Provider Spotlight Program linking therapists to journalists and media. What do these engagement choices reveal about its brand strategy?

Participation in the Behavioral Health Tech Conference and the Provider Spotlight Program both target supply-side credibility — therapists and clinical buyers — rather than consumer brand building. This reflects a marketplace logic: if Grow Therapy is the preferred platform among high-quality providers, consumer demand follows through provider referrals and reputation. The media-linking component of the Provider Spotlight Program also functions as earned media for the platform without direct advertising spend. Collectively, these choices suggest a provider-first brand strategy consistent with a company that sees therapist acquisition and retention as its primary growth constraint.

Powered by ForesightIQ · Competitive intelligence from digital exhaust